Table 5.
Distribution of anti-hyperglycemic agent classes by comorbidities
| No comorbidity (N = 151) | CVD (N = 52) | CHF (N = 2) | CKD stage 1 | CKD stage 2 | CKD stage 3 | CKD stage 4 | CKD stage 5 | CKD (N = 133) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Metformin | 132 (87.4%) | 36 (69%) | 15 (71%) | 55 (89%) | 27 (63%) | 1 (25%) | 1 (33%) | 99 (74.4%) | ||
| SUs | 52 (34.4%) | 13 (25%) | 13 (62%) | 24 (39%) | 7 (16%) | 2 (50%) | 0 | 46 (35%) | ||
| Meglitinides | 1 (0.7%) | 1 (2%) | 1 (2%) | 1 2%) | 2 (1.5%) | |||||
| TZD | 8 (5.3%) | 1 (2%) | 1 (5%) | 1 (0.8%) | ||||||
| GLP-1RA | 17 (11.3%) | 12 (23%) | 8 (38%) | 11 (18%) | 13 (30%) | 1 (25%) | 1 (33%) | 34 (25.6%) | ||
| DPP-4i | 72 (47.7%) | 28 (53.8%) | 1 (50%) | 10 (48%) | 27 (44%) | 16 (37%) | 0 | 2 (67%) | 55 (41.4%) | |
| SGLT2i | 3 (35.1%) | 20 (38.5%) | 1 (50%) | 13 (62%) | 21 (34%) | 15 (35%) | 49 (37%) | |||
| Insulin | 25 (16.6%) | 30 (58%) | 2 (100%) | 14 (67%) | 27 (44%) | 30 (70%) | 3 (75%) | 3 (100%) | 77 (58%) | |
| Alpha glucosidase inhibitors | 2 (1.3%) | 0 | 2 (100%) | 0 | ||||||
SU sulfonylurea, TZD thiazolidinediones, GLP-1RA GLP-1 receptor agonists, DPP4i dipeptidyl peptidase 4 inhibitor, SGLT2i sodium-glucose co-transporter-2 inhibitors